Figure 8: The MET inhibitor crizotinib restores rociletinib sensitivity in a patient-derived NSCLC xenograft model of innate rociletinib resistance. | Nature Communications

Figure 8: The MET inhibitor crizotinib restores rociletinib sensitivity in a patient-derived NSCLC xenograft model of innate rociletinib resistance.

From: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Figure 8

Mice bearing LU0858 NSCLC patient-derived xenograft tumours (L858R mutant and 14-copy MET amplification) were orally administered rociletinib, crizotinib or the combination using the doses and schedules indicated (n=10 per group). The endpoint tumour volumes between the crizotinib and combination groups on day 22 were compared using a paired two tailed student’s t-test (n=10; ****P<0.0001).

Back to article page